FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Roy Herbst

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Takeshi Isobe; Satoshi Itasaka; Jörg J Jacoby; Peter J Koo; Daniel Morgensztern; Amir Onn; Michael S O'Reilly; Keiko Shibuya; Tomoaki Shintani; Wenjuan Wu; Roy S Herbst
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
Pierre Saintigny; Luisa M Solis Soto; Ignacio I Wistuba; Li Zhang; Young-Ho Ahn; Carmen Behrens; Yulong Chen; Baruch Erez; Sangeeta Goswami; Roy S Herbst; John V Heymach; Waun Ki Hong; Edward S Kim; Jonathan M Kurie; J Jack Lee; Steven Lin; Scott M Lippman; Diane Liu; Erminia Massarelli; Michael S O'Reilly; Yuan Ping; Ja Seok Koo
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.
Sarah B Goldberg; Julie L Boyer; Joseph Schlessinger; Roy S Herbst
A step towards treating KRAS-mutant NSCLC.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Roy Herbst (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Takeshi Isobe; Satoshi Itasaka; Jörg J Jacoby; Peter J Koo; Daniel Morgensztern; Amir Onn; Michael S O'Reilly; Keiko Shibuya; Tomoaki Shintani; Wenjuan Wu; Roy S Herbst
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(2):140-6.
2013: Pierre Saintigny; Luisa M Solis Soto; Ignacio I Wistuba; Li Zhang; Young-Ho Ahn; Carmen Behrens; Yulong Chen; Baruch Erez; Sangeeta Goswami; Roy S Herbst; John V Heymach; Waun Ki Hong; Edward S Kim; Jonathan M Kurie; J Jack Lee; Steven Lin; Scott M Lippman; Diane Liu; Erminia Massarelli; Michael S O'Reilly; Yuan Ping; Ja Seok Koo
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.
Cancer research 2013;73(2):571-82.
2013: Sarah B Goldberg; Julie L Boyer; Joseph Schlessinger; Roy S Herbst
A step towards treating KRAS-mutant NSCLC.
The lancet oncology 2013;14(1):3-5.
2012: Laurie E Gaspar; E Greer Gay; Roy S Herbst; Erica J McNamara; Joe B Putnam; Jeffrey Crawford; James A Bonner
Small-cell lung cancer: prognostic factors and changing treatment over 15 years.
Clinical lung cancer 2012;13(2):115-22.
2012: Nathan T Ihle; Edward S Kim; Jill E Larsen; J Jack Lee; Scott M Lippman; Suyu Liu; John D Minna; Vassiliki A Papadimitrakopoulou; Mena F Abdelmelek; George R Blumenschein; Lauren A Byers; Lu Chen; Kevin R Coombes; Lixia Diao; Roy S Herbst; John V Heymach; Waun K Hong; Pierre Saintigny; Ximing Tang; Anne Tsao; Jing Wang; Ignacio I Wistuba; Shuxing Zhang; Garth Powis
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Journal of the National Cancer Institute 2012;104(3):228-39.
2011: Fei Yang; Ximing Tang; Erick Riquelme; Carmen Behrens; Monique B Nilsson; Uma Giri; Marileila Varella-Garcia; Lauren A Byers; Heather Y Lin; Jing Wang; Maria G Raso; Luc Girard; Kevin Coombes; J Jack Lee; Roy S Herbst; John D Minna; John V Heymach; Ignacio I Wistuba
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.
Cancer research 2011;71(16):5512-21.
2011: George R Blumenschein; Hak Choy; Walter J. CURRAN; Philip O Doescher; Frank V Fossella; Roy S Herbst; Rebecca Paulus; Francisco Robert; Maria Werner-Wasik; Ritsuko Komaki
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(17):2312-8.
2011: Hai T Tran; Ralph G Zinner; George R Blumenschein; Yun W Oh; Vassiliki A Papadimitrakopoulou; Edward S Kim; Charles Lu; Mubashira Malik; Bert L Lum; Roy S Herbst
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Investigational new drugs 2011;29(3):499-505.
2011: Roy S Herbst; Rafat Ansari; Frederique Bustin; Patrick Flynn; Lowell Hart; Gregory A Otterson; Gordana Vlahovic; Chang-Heok Soh; Paula O'Connor; John Hainsworth
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
Lancet 2011;377(9780):1846-54.
2010: Caleb T Chu; Jörg J Jacoby; Roy S Herbst
Future directions of monoclonal antibody use in personalized lung cancer therapy.
Oncology (Williston Park, N.Y.) 2010;24(13):1226-8.
2010: Roy S Herbst; Karen Kelly; Kari Chansky; Philip C Mack; Wilbur A Franklin; Fred R Hirsch; James N Atkins; Shaker R Dakhil; Kathy S Albain; Edward S Kim; Mary Redman; John J Crowley; David R Gandara
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(31):4747-54.
2010: David P Carbone; J Stuart Salmon; Dean Billheimer; Heidi Chen; Alan B Sandler; Heinrich Roder; Joanna Roder; Maxim Tsypin; Roy S Herbst; Anne S Tsao; Hai T Tran; Thao P Dang
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.
Lung cancer (Amsterdam, Netherlands) 2010;69(3):337-40.
2010: Roy S Herbst; Yan Sun; Wilfried E E Eberhardt; Paul Germonpré; Nagahiro Saijo; Caicun Zhou; Jie Wang; Longyun Li; Fairooz Kabbinavar; Yukito Ichinose; Shukui Qin; Li Zhang; Bonne Biesma; John V Heymach; Peter Langmuir; Sarah J Kennedy; Hiroomi Tada; Bruce E Johnson
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
The lancet oncology 2010;11(7):619-26.
2010: Jörg J Jacoby; Baruch Erez; Maria V Korshunova; Ryan R Williams; Kazuhisa Furutani; Osamu Takahashi; Lynn Kirkpatrick; Scott M Lippman; Garth Powis; Michael S O'Reilly; Roy S Herbst
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(7):940-9.
2010: Charles Lu; J Jack Lee; Ritsuko Komaki; Roy S Herbst; Lei Feng; William K Evans; Hak Choy; Pierre Desjardins; Benjamin T Esparaz; Mylene T Truong; Scott Saxman; Joseph Kelaghan; Archie Bleyer; Michael J Fisch
Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.
Journal of the National Cancer Institute 2010;102(12):859-65.
2010: Roy S Herbst; S Gail Eckhardt; Razelle Kurzrock; Scot W Ebbinghaus; Peter J O'Dwyer; Michael S Gordon; William Novotny; Meredith A Goldwasser; Tanyifor M Tohnya; Bert L Lum; Avi Ashkenazi; Adrian M Jubb; David S Mendelson
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(17):2839-46.
2010: Kasisomayajula Viswanath; Roy S Herbst; Stephanie R Land; Scott J Leischow; Peter G Shields
Tobacco and cancer: an American Association for Cancer Research policy statement.
Cancer research 2010;70(9):3419-30.
2010: William N William; Fadlo R Khuri; Frank V Fossella; Bonnie S Glisson; Ralph G Zinner; J Jack Lee; Roy S Herbst; Scott M Lippman; Edward S Kim
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
American journal of clinical oncology 2010;33(2):148-52.
2010: D Ross Camidge; Roy S Herbst; Michael S Gordon; S Gail Eckhardt; Razelle Kurzrock; Blythe Durbin; Josephine Ing; Tanyifor M Tohnya; Jason Sager; Avi Ashkenazi; Gordon Bray; David Mendelson
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(4):1256-63.
2010: Jieru Meng; Bingbing Dai; Bingliang Fang; B Nebiyou Bekele; William G Bornmann; Duoli Sun; Zhenghong Peng; Roy S Herbst; Vassiliki A Papadimitrakopoulou; John D Minna; Michael Peyton; Jack A Roth
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
PloS one 2010;5(11):e14124.
2010: Anne S Tsao; Jack A Roth; Roy S Herbst
Surgery: Future directions in multimodality therapy for NSCLC.
Nature reviews. Clinical oncology 2010;7(1):10-2.
2009: William Pao; Mark G Kris; A John Iafrate; Marc Ladanyi; Pasi A Janne; Ignacio I Wistuba; Ryn Miake-Lye; Roy S Herbst; David P Carbone; Bruce E Johnson; Thomas J Lynch
Integration of molecular profiling into the lung cancer clinic.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(17):5317-22.
2009: Emer O Hanrahan; Anderson Ryan; Helen Mann; Sarah J Kennedy; Peter Langmuir; Ronald B Natale; Roy S Herbst; Bruce E Johnson; John V Heymach
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3600-9.
2009: Roy S Herbst; Fred R Hirsch
Patient selection criteria and the FLEX Study.
Lancet 2009;373(9674):1497-8.
2009: Chaan S Ng; Yoshihisa Kodama; Nizar A Mullani; Bruce J Barron; Wei Wei; Roy S Herbst; James L Abbruzzese; Chusilp Charnsangavej
Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study.
Journal of computer assisted tomography 2009;33(3):460-5.
2009: Edward S Kim; Ann M Mauer; William N William; Hai T Tran; Diane Liu; Jack J Lee; Paul Windt; Waun Ki Hong; Everett E Vokes; Roy S Herbst
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.
Cancer 2009;115(8):1713-22.
2009: William N William; Edward S Kim; Roy S Herbst
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck.
Nature clinical practice. Oncology 2009;6(3):132-3.
2009: Giuseppe Giaccone; Renee B Iacona; Abderrahim Fandi; Mette Janas; Judith S Ochs; Roy S Herbst; David H Johnson
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
Journal of cancer research and clinical oncology 2009;135(3):467-76.
2009: Roy S Herbst; Thomas J Lynch; Alan B Sandler
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy.
Clinical lung cancer 2009;10(1):20-7.
2008: Roy S Herbst; Alan B Sandler
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
The oncologist 2008;13(11):1166-76.
2008: Roy S Herbst; John V Heymach; Scott M Lippman
Lung cancer.
The New England journal of medicine 2008;359(13):1367-80.
2008: Avi Ashkenazi; Roy S Herbst
To kill a tumor cell: the potential of proapoptotic receptor agonists.
The Journal of clinical investigation 2008;118(6):1979-90.
2008: Edith M Marom; Carlos H Martinez; Mylene T Truong; Lei Xiudong; Bradley S Sabloff; Reginald F Munden; Gregory W Gladish; Roy S Herbst; Rodolfo C Morice; David J Stewart; Carlos A Jimenez; George R Blumenschein; Amir Onn
Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(4):351-7.
2008: Nizar A Mullani; Roy S Herbst; Roger G O'Neil; K Lance Gould; Bruce J Barron; James L Abbruzzese
Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(4):517-23.
2008: Vincent A Miller; Gregory J Riely; Maureen F Zakowski; Allan R Li; Jyoti D Patel; Robert T Heelan; Mark G Kris; Alan B Sandler; David P Carbone; Anne Tsao; Roy S Herbst; Glenn Heller; Marc Ladanyi; William Pao; David H Johnson
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1472-8.
2008: Roy S Herbst
Current and future strategies for antiangiogenic agents in non-small-cell lung cancer.
Clinical lung cancer 2008;9 Suppl 2():S50.
2008: Yun Oh; Roy S Herbst; Howard Burris; Ann Cleverly; Luna Musib; Michael Lahn; Gerold Bepler
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1135-41.
2008: Jair Bar; Roy S Herbst; Amir Onn
Multitargeted inhibitors in lung cancer: new clinical data.
Clinical lung cancer 2008;9 Suppl 3():S92-9.
2007: Keiko Shibuya; Ritsuko Komaki; Tomoaki Shintani; Satoshi Itasaka; Anderson Ryan; Juliane M Jürgensmeier; Luka Milas; Kian Ang; Roy S Herbst; Michael S O'Reilly
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
International journal of radiation oncology, biology, physics 2007;69(5):1534-43.
2007: Roy S Herbst; Vincent J O'Neill; Louis Fehrenbacher; Chandra P Belani; Philip D Bonomi; Lowell Hart; Ostap Melnyk; David A Ramies; Ming Lin; Alan B Sandler
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4743-50.
2007: Roy S Herbst; Angela M Davies; Ronald B Natale; Thao P Dang; Joan H Schiller; Linda L Garland; Vincent A Miller; David S Mendelson; Annick D Van den Abbeele; Yulia Melenevsky; Daniel J de Vries; David A Eberhard; Benjamin Lyons; Stuart G Lutzker; Bruce E Johnson
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):6175-81.
2007: Wenjuan Wu; Michael S O'Reilly; Robert R Langley; Rachel Tsan; Cheryl H Baker; Neby Bekele; Xi Ming Tang; Amir Onn; Isaiah J Fidler; Roy S Herbst
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
Molecular cancer therapeutics 2007;6(10):2652-63.
2007: Roy S Herbst; Yun Oh; Asavari Wagle; Michael Lahn
Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4641-6.
2007: Rebecca D Pentz; Anne L Flamm; Jeremy Sugarman; Marlene Z Cohen; Zhiheng Xu; Roy S Herbst; James L Abbruzzese
Who should go first in trials with scarce agents? The views of potential participants.
IRB 2007;29(4):1-6.
2007: Eugene H Huang; Zhongxing Liao; James D Cox; Thomas Guerrero; Joe Y Chang; Melenda Jeter; Yerko O Borghero; Xiong Wei; Frank V Fossella; Roy S Herbst; George R Blumenschein; Cesar Moran; Pamela K Allen; Ritsuko Komaki
Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
International journal of radiation oncology, biology, physics 2007;68(3):779-85.
2007: Marlene Z Cohen; Jacquelyn Slomka; Rebecca D Pentz; Anne L Flamm; David Gold; Roy S Herbst; James L Abbruzzese
Phase I participants' views of quality of life and trial participation burdens.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2007;15(7):885-90.
2007: Erminia Massarelli; Marileila Varella-Garcia; Ximing Tang; Ana C Xavier; Natalie Ozburn; Diane D Liu; B Nebiyou Bekele; Roy S Herbst; Ignacio I Wistuba
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2890-6.
2007: Satoshi Itasaka; Ritsuko Komaki; Roy S Herbst; Keiko Shibuya; Tomoaki Shintani; Nancy Hunter; Amir Onn; Corazon D Bucana; Luka Milas; K. Kian Ang; Michael S O'Reilly
Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice.
International journal of radiation oncology, biology, physics 2007;67(3):870-8.
2007: Wenjuan Wu; Amir Onn; Takeshi Isobe; Satoshi Itasaka; Robert R Langley; Tomoaki Shitani; Keiko Shibuya; Ritsuko Komaki; Anderson Ryan; Isaiah J Fidler; Roy S Herbst; Michael S O'Reilly
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Molecular cancer therapeutics 2007;6(2):471-83.
2007: Roy S Herbst; John V Heymach; Michael S O'Reilly; Amir Onn; Anderson Ryan
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.
Expert opinion on investigational drugs 2007;16(2):239-49.
2006: Roy S Herbst
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Clinical lung cancer 2006;8 Suppl 1():S23-30.
2006: Seung-Hyun Oh; Ok-Hee Lee; Claudia P Schroeder; Yun W Oh; Shi Ke; Hee-Jae Cha; Rang-Woon Park; Amir Onn; Roy S Herbst; Chun Li; Ho-Young Lee
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
Molecular cancer therapeutics 2006;5(11):2685-95.
2006: Roy S Herbst
Therapeutic options to target angiogenesis in human malignancies.
Expert opinion on emerging drugs 2006;11(4):635-50.
2006: Michael A Carducci; Luna Musib; Merrill S Kies; Roberto Pili; Mylene Truong; Julie R Brahmer; Patricia Cole; Rana Sullivan; Jeanne Riddle; Jill Schmidt; Nathan Enas; Vikram Sinha; Donald E Thornton; Roy S Herbst
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(25):4092-9.
2006: Lisa J Green; Philip Marder; Chad Ray; Carolyn A Cook; Susan Jaken; Luna Musib; Roy S Herbst; Michael A Carducci; Carolyn D Britten; Michele Basche; S Gail Eckhardt; Donald Thornton
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 1):3408-15.
2006: Sheeba K Thomas; Frank V Fossella; Diane Liu; Rainell Schaerer; Anne S Tsao; Merrill S Kies; Katherine M W Pisters; George R Blumenschein; Bonnie S Glisson; J Jack Lee; Roy S Herbst; Ralph G Zinner
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.
Clinical lung cancer 2006;7(5):326-31.
2006: Erminia Massarelli; Roy S Herbst
Use of novel second-line targeted therapies in non-small cell lung cancer.
Seminars in oncology 2006;33(1 Suppl 1):S9-16.
2005: Francisco Robert; George R Blumenschein; Roy S Herbst; Frank V Fossella; Jennifer Tseng; Mansoor N Saleh; Michael Neil Needle
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9089-96.
2005: Ralph G Zinner; Frank V Fossella; Gregory W Gladish; Bonnie S Glisson; George R Blumenschein; Vassiliki A Papadimitrakopoulou; Katherine M W Pisters; Edward S Kim; Yun W Oh; Beverly O Peeples; Zhishen Ye; Rafael E Curiel; Coleman K Obasaju; Waun Ki Hong; Roy S Herbst
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.
Cancer 2005;104(11):2449-56.
2005: Daphne W Bell; Thomas J Lynch; Sara M Haserlat; Patricia Neal; Ross A Okimoto; Brian W Brannigan; Dennis C Sgroi; Beth Muir; Markus J Riemenschneider; Renee Bailey Iacona; Annetta D Krebs; David H Johnson; Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Masahiro Fukuoka; Mark G Kris; José Baselga; Judith S Ochs; Daniel A Haber
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):8081-92.
2005: Amir Onn; Du Hwan Choe; Roy S Herbst; Arlene M Correa; Reginald F Munden; Mylene T Truong; Ara A Vaporciyan; Takeshi Isobe; Michael Z Gilcrease; Edith M Marom
Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome.
Radiology 2005;237(1):342-7.
2005: Roy S Herbst; Diane Prager; Robert Hermann; Louis Fehrenbacher; Bruce E Johnson; Alan B Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David A Ramies; David H Johnson; Vincent A Miller
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5892-9.
2005: David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Janne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5900-9.
2005: Roy S Herbst; Matthew A Arquette; Dong M Shin; Karel Dicke; Everett E Vokes; Nozar Azarnia; Waun Ki Hong; Merrill S Kies
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5578-87.
2005: Amir Onn; Roy S Herbst
What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?
Nature clinical practice. Oncology 2005;2(6):290-1.
2005: Takeshi Isobe; Roy S Herbst; Amir Onn
Current management of advanced non-small cell lung cancer: targeted therapy.
Seminars in oncology 2005;32(3):315-28.
2005: Roy S Herbst
Role of novel targeted therapies in the clinic.
British journal of cancer 2005;92 Suppl 1():S21-7.
2005: Roy S Herbst; Amir Onn; Alan B Sandler
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(14):3243-56.
2005: Laurie E Gaspar; E Greer Gay; Jeffrey Crawford; Joe B Putnam; Roy S Herbst; James A. Bonner
Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base.
Clinical lung cancer 2005;6(6):355-60.
2005: David Cella; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Anne Heyes; Judith S Ochs; Michael K Wolf; Andrea C Kay; Mark G Kris; Ronald B Natale
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2946-54.
2005: Roy S Herbst; David H Johnson; Eric Mininberg; David P Carbone; Ted Henderson; Edward S Kim; George R Blumenschein; Jack J Lee; Diane D Liu; Mylene T Truong; Waun Ki Hong; Hai Tran; Anne S Tsao; Dong Xie; David A Ramies; Robert Mass; Somasekar Seshagiri; David A Eberhard; Sean K Kelley; Alan B Sandler
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2544-55.
2005: Ryohei Sasaki; Ritsuko Komaki; Homer A Macapinlac; Jeremy J Erasmus; Pamela Allen; Kenneth Forster; Joe B Putnam; Roy S Herbst; Cesar A Moran; Donald A Podoloff; Jack A Roth; James D Cox
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(6):1136-43.
2005: Darren W Davis; Ryan Takamori; Chandrajit P Raut; Henry Q Xiong; Roy S Herbst; Walter M Stadler; John V Heymach; George D Demetri; Asif Rashid; Yu Shen; Sijin Wen; James L Abbruzzese; David J McConkey
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):678-89.
2005: Roy S Herbst; Patricia M LoRusso; Takeshi Isobe; Herbert I Hurwitz
Angiogenesis pathway inhibitors.
Cancer chemotherapy and biological response modifiers 2005;22():225-45.
2004: Amir Onn; Takeshi Isobe; Wenjuan Wu; Satoshi Itasaka; Tomoaki Shintani; Keiko Shibuya; Yokoi Kenji; Michael S O'Reilly; Isaiah J Fidler; Roy S Herbst
Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8613-9.
2004: Roy S Herbst; Alan B Sandler
Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.
Clinical lung cancer 2004;6 Suppl 1():S7-S19.
2004: Roy S Herbst; Masahiro Fukuoka; José Baselga
Gefitinib--a novel targeted approach to treating cancer.
Nature reviews. Cancer 2004;4(12):956-65.
2004: Cesare Gridelli; Erminia Massarelli; Paolo Maione; Antonio Rossi; Roy S Herbst; Amir Onn; Fortunato Ciardiello
Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.
Cancer 2004;101(8):1733-44.
2004: Hai T Tran; George R Blumenschein; Charles Lu; Christina A Meyers; Vassiliki A Papadimitrakopoulou; Frank V Fossella; Ralph G Zinner; Timothy Madden; Lori G Smythe; Vinay K Puduvalli; Reginald F Munden; Mylene T Truong; Roy S Herbst
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.
Cancer chemotherapy and pharmacology 2004;54(4):308-14.
2004: Roy S Herbst
EGFR inhibition in NSCLC: the emerging role of cetuximab.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 2():S41-51.
2004: Ralph G Zinner; Frank V Fossella; Roy S Herbst
Pemetrexed in advanced NSCLC: a review of the clinical data.
Oncology (Williston Park, N.Y.) 2004;18(8 Suppl 5):54-62.
2004: Roy S Herbst; Stanley R Frankel
Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4245s-4248s.
2004: Fadlo R Khuri; Bonnie S Glisson; Edward S Kim; Paul Statkevich; Peter F Thall; Michael L Meyers; Roy S Herbst; Reginald F Munden; Craig Tendler; Yali Zhu; Sandra Bangert; Elizabeth Thompson; Charles Lu; Xue-Mei Wang; Dong M Shin; Merrill S Kies; Vassiliki A Papadimitrakopoulou; Frank V Fossella; Paul Kirschmeier; W Robert Bishop; Waun Ki Hong
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):2968-76.
2004: Ralph G Zinner; Roy S Herbst
Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data.
Clinical lung cancer 2004;5 Suppl 2():S67-74.
2004: Ritsuko Komaki; Jin Soo Lee; Luka Milas; Hoon K Lee; Frank V Fossella; Roy S Herbst; Pamela K Allen; Zhongxing Liao; Craig W Stevens; Charles Lu; Ralph G Zinner; Vassiliki A Papadimitrakopoulou; Merrill S Kies; George R Blumenschein; Katherine M W Pisters; Bonnie S Glisson; Jonathan M Kurie; Bunyamin Kaplan; Veronica P Garza; Deidre Mooring; Susan L Tucker; James D Cox
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
International journal of radiation oncology, biology, physics 2004;58(5):1369-77.
2004: Ralph G Zinner; Bonnie S Glisson; Frank V Fossella; Katherine M W Pisters; Merrill S Kies; Pamela M Lee; Erminia Massarelli; Bradley Sabloff; Herbert A Fritsche; Jae Y Ro; Nelson G Ordonez; Hai T Tran; Ying Yang; Terry L Smith; Robert D Mass; Roy S Herbst
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.
Lung cancer (Amsterdam, Netherlands) 2004;44(1):99-110.
2004: Roy S Herbst; Giuseppe Giaccone; Joan H Schiller; Ronald B Natale; Vincent A Miller; Christian Manegold; Giorgio V Scagliotti; Rafael Rosell; Ira Oliff; James A Reeves; Michael K Wolf; Annetta D Krebs; Steven D Averbuch; Judith S Ochs; John Grous; Abderrahim Fandi; David H Johnson
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):785-94.
2004: Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio V Scagliotti; Rafael Rosell; Vincent A Miller; Ronald B Natale; Joan H Schiller; Joachim von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):777-84.
2004: Roy S Herbst; Alan B Sandler
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?
The oncologist 2004;9 Suppl 1():19-26.
2004: Roy S Herbst
Review of epidermal growth factor receptor biology.
International journal of radiation oncology, biology, physics 2004;59(2 Suppl):21-6.
2004: Amir Onn; Arlene M Correa; Michael Z Gilcrease; Takeshi Isobe; Erminia Massarelli; Corazon D Bucana; Michael S O'Reilly; Waun Ki Hong; Isaiah J Fidler; Joe B Putnam; Roy S Herbst
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):136-43.
2004: Darren W Davis; Yu Shen; Nizar A Mullani; Sijin Wen; Roy S Herbst; Michael O'Reilly; James L Abbruzzese; David J McConkey
Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):33-42.
2003: Roy S Herbst; Paul A Bunn
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(16 Pt 1):5813-24.
2003: Amir Onn; Takeshi Isobe; Satoshi Itasaka; Wenjuan Wu; Michael S O'Reilly; Waun Ki Hong; Isaiah J Fidler; Roy S Herbst
Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5532-9.
2003: Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan B Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
JAMA : the journal of the American Medical Association 2003;290(16):2149-58.
2003: Roy S Herbst; Fadlo R Khuri
Mode of action of docetaxel - a basis for combination with novel anticancer agents.
Cancer treatment reviews 2003;29(5):407-15.
2003: Roy S Herbst; Lisa A Hammond; David P Carbone; Hai T Tran; Kenneth J Holroyd; Avinash Desai; Jon I Williams; B Nebiyou Bekele; Howard Hait; Victoria Allgood; Stephen Solomon; Joan H Schiller
A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4108-15.
2003: Roy S Herbst; Merrill S Kies
Gefitinib: current and future status in cancer therapy.
Clinical advances in hematology & oncology : H&O 2003;1(8):466-72.
2003: Roy S Herbst; Michael S O'Reilly
The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer.
Seminars in oncology 2003;30(4 Suppl 9):113-23.
2003: D W Davis; D J McConkey; J L Abbruzzese; Roy S Herbst
Surrogate markers in antiangiogenesis clinical trials.
British journal of cancer 2003;89(1):8-14.
2003: Jeremy J Erasmus; Gregory W Gladish; Lyle D Broemeling; Bradley S Sabloff; Mylene T Truong; Roy S Herbst; Reginald F Munden
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2574-82.
2003: Roy S Herbst
Erlotinib (Tarceva): an update on the clinical trial program.
Seminars in oncology 2003;30(3 Suppl 7):34-46.
2003: Patricia M LoRusso; Roy S Herbst; Danny Rischin; Malcolm Ranson; Hilary Calvert; Eric Raymond; Dirk Kieback; Stan Kaye; Luca Gianni; Adrian Harris; Thomas Bjork; Anne-Marie Maddox; Mace L Rothenberg; Eric J Small; Eric H Rubin; Andrea Feyereislova; Anne Heyes; Steven D Averbuch; Judith S Ochs; José Baselga
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2040-8.
2003: Roy S Herbst; Patricia M LoRusso; Michele Purdom; Deborah Ward
Dermatologic side effects associated with gefitinib therapy: clinical experience and management.
Clinical lung cancer 2003;4(6):366-9.
2003: Darren W Davis; David J McConkey; Wei Zhang; Roy S Herbst
Antiangiogenic tumor therapy.
BioTechniques 2003;34(5):1048-50, 1052, 1054 passim.
2003: Roy S Herbst
Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Seminars in oncology 2003;30(1 Suppl 1):30-8.
2003: George R Blumenschein; Roy S Herbst
Integration of targeted therapies in gemcitabine chemotherapy regimens.
Clinical lung cancer 2003;4(4):217-23.
2003: Roy S Herbst; Amir Onn; John Mendelsohn
The role of growth factor signaling in malignancy.
Cancer treatment and research 2003;115():19-72.
2003: Erminia Massarelli; F Andre; Diane D Liu; J Jack Lee; M Wolf; A Fandi; Judith S Ochs; T Le Chevalier; Frank V Fossella; Roy S Herbst
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;39(1):55-61.
2003: Amir Onn; Roy S Herbst
Angiogenesis, metastasis, and lung cancer. An overview.
Methods in molecular medicine 2003;74():329-48.
2002: Roy S Herbst; Timothy L Madden; Hai T Tran; George R Blumenschein; Christina A Meyers; Lee F Seabrooke; Fadlo R Khuri; Vinay K Puduvalli; Victoria Allgood; Herbert A Fritsche; Leslie Hinton; Robert A Newman; Elizabeth A Crane; Frank V Fossella; Margaret Dordal; Thomas Goodin; Waun Ki Hong
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(22):4440-7.
2002: Kerim Kaban; Roy S Herbst
Angiogenesis as a target for cancer therapy.
Hematology/oncology clinics of North America 2002;16(5):1125-71.
2002: Roy S Herbst; Waun Ki Hong
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Seminars in oncology 2002;29(5 Suppl 14):18-30.
2002: Roy S Herbst; Anne-Marie Maddox; Mace L Rothenberg; Eric J Small; Eric H Rubin; José Baselga; Federico Rojo; Waun Ki Hong; Helen Swaisland; Steven D Averbuch; Judith S Ochs; Patricia M LoRusso
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18):3815-25.
2002: Roy S Herbst; Nizar A Mullani; Darren W Davis; Kenneth R Hess; David J McConkey; Chusilp Charnsangavej; Michael S O'Reilly; Hyung Woo Kim; Cheryl Baker; Jennifer Roach; Lee M Ellis; Asif Rashid; James Pluda; Corazon D Bucana; Timothy L Madden; Hai T Tran; James L Abbruzzese
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18):3804-14.
2002: Roy S Herbst; Kenneth R Hess; Hai T Tran; Jennifer E Tseng; Nizar A Mullani; Chusilp Charnsangavej; Timothy Madden; Darren W Davis; David J McConkey; Michael S O'Reilly; Lee M Ellis; James Pluda; Waun Ki Hong; James L Abbruzzese
Phase I study of recombinant human endostatin in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18):3792-803.
2002: Rebecca D Pentz; Anne L Flamm; Jeremy Sugarman; Marlene Z Cohen; G Daniel Ayers; Roy S Herbst; James L Abbruzzese
Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18):3785-91.
2002: Roy S Herbst
Targeted therapy in non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2002;16(9 Suppl 9):19-24.
2002: Roy S Herbst; Fadlo R Khuri; Charles Lu; Diane D Liu; Frank V Fossella; Bonnie S Glisson; Katherine M W Pisters; Dong M Shin; Vassiliki A Papadimitrakopoulou; Jonathan M Kurie; George R Blumenschein; Merrill S Kies; Ralph G Zinner; Maria S Jung; Robert Lu; J Jack Lee; Reginald F Munden; Waun Ki Hong; Jin Soo Lee
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Cancer 2002;95(2):340-53.
2002: Ralph G Zinner; Jeri Kim; Roy S Herbst
Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results.
Lung cancer (Amsterdam, Netherlands) 2002;37(1):17-27.
2002: Edward S Kim; Roy S Herbst
Angiogenesis inhibitors in lung cancer.
Current oncology reports 2002;4(4):325-33.
2002: Dominic Fan; Seiji Yano; Hisashi Shinohara; Carmen C Solorzano; Melissa Van Arsdall; Corazon D Bucana; Sen Pathak; Ewa Kruzel; Roy S Herbst; Amir Onn; Jennifer S Roach; Masanori Onda; Qing-Cheng Wang; Ira Pastan; Isaiah J Fidler
Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.
Molecular cancer therapeutics 2002;1(8):595-600.
2002: Roy S Herbst
ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
Expert opinion on investigational drugs 2002;11(6):837-49.
2002: Elizabeth S Waxman; Roy S Herbst
The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma.
Seminars in oncology nursing 2002;18(2 Suppl 2):20-9.
2002: Edward S Kim; Merrill S Kies; Roy S Herbst
Novel therapeutics for head and neck cancer.
Current opinion in oncology 2002;14(3):334-42.
2002: Roy S Herbst
Targeted therapy using novel agents in the treatment of non-small-cell lung cancer.
Clinical lung cancer 2002;3 Suppl 1():S30-8.
2002: Roy S Herbst; Dong M Shin
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy.
Cancer 2002;94(5):1593-611.
2002: Roy S Herbst; Manuel Hidalgo; A Scott Pierson; Scott N Holden; Michael Bergen; S Gail Eckhardt
Angiogenesis inhibitors in clinical development for lung cancer.
Seminars in oncology 2002;29(1 Suppl 4):66-77.
2002: Roy S Herbst; Corey J Langer
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Seminars in oncology 2002;29(1 Suppl 4):27-36.
2002: Erminia Massarelli; Amir Onn; Ralph G Zinner; Fadlo R Khuri; Edward S Kim; Roy S Herbst
New targets for the treatment of advanced non-small cell lung cancer.
Cancer chemotherapy and biological response modifiers 2002;20():717-61.
2002: Roy S Herbst; Merrill S Kies
ZD1839 (Iressa) in non-small cell lung cancer.
The oncologist 2002;7 Suppl 4():9-15.
2001: Edward S Kim; C Lu; Fadlo R Khuri; M Tonda; Bonnie S Glisson; D Liu; M Jung; Waun Ki Hong; Roy S Herbst
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2001;34(3):427-32.
2001: Jennifer E Tseng; Bonnie S Glisson; Fadlo R Khuri; Dong M Shin; Jeffrey N Myers; Adel K El-Naggar; Jennifer S Roach; Lawrence E Ginsberg; Peter F Thall; Xuemei Wang; S Teddy; KN Lawhorn; R E Zentgraf; G D Steinhaus; James Pluda; James L Abbruzzese; Waun Ki Hong; Roy S Herbst
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.
Cancer 2001;92(9):2364-73.
2001: Edward S Kim; Fadlo R Khuri; Roy S Herbst
Epidermal growth factor receptor biology (IMC-C225).
Current opinion in oncology 2001;13(6):506-13.
2001: Roy S Herbst; Fadlo R Khuri; Frank V Fossella; Bonnie S Glisson; Merrill S Kies; Katherine M W Pisters; Jeanne Riddle; K A Terry; J S Lee
ZD1839 (Iressa) in non-small-cell lung cancer.
Clinical lung cancer 2001;3(1):27-32.
2001: Roy S Herbst; A T Lee; Hai T Tran; James L Abbruzzese
Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin.
Current oncology reports 2001;3(2):131-40.
2000: S Yano; H Shinohara; Roy S Herbst; H Kuniyasu; Corazon D Bucana; Lee M Ellis; Darren W Davis; David J McConkey; Isaiah J Fidler
Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis.
Cancer research 2000;60(17):4959-67.
2000: S Yano; Roy S Herbst; H Shinohara; B Knighton; Corazon D Bucana; Jerald J Killion; J Wood; Isaiah J Fidler
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):957-65.
2000: Roy S Herbst; S Yano; H Kuniyasu; Fadlo R Khuri; Corazon D Bucana; F Guo; Diane Liu; B Kemp; J Jack Lee; Waun Ki Hong; Isaiah J Fidler
Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):790-7.
1999: Roy S Herbst; R Lilenbaum
Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer.
Seminars in oncology 1999;26(5 Suppl 16):67-70; discussion 71-2.